Drug intelligence / Profile preview

bevacizumab + lobaplatin + pemetrexed + temozolomide

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Intrapleural, Oral

Overview

A combination therapy consisting of four anticancer agents. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing angiogenesis. Lobaplatin is a platinum-based chemotherapy agent. Pemetrexed is an antifolate antineoplastic agent. Temozolomide is an alkylating agent. This specific four-drug combination would likely target multiple cancer pathways simultaneously, including tumor angiogenesis and DNA replication.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + lobaplatin + pemetrexed + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + lobaplatin + pemetrexed + temozolomide.

Explore the full profile